Literature DB >> 14920496

Pyrazinoic acid amide; an agent active against experimental murine tuberculosis.

M SOLOTOROVSKY, F J GREGORY, E J IRONSON, E J BUGIE, R C O'NEILL, R PFISTER.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID/derivatives; TUBERCULOSIS/experimental

Mesh：

Substances：

Year:  1952        PMID： 14920496     DOI： 10.3181/00379727-79-19447

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


× No keyword cloud information.
  11 in total

1.  Hyperuricaemia due to pyrazinamide.

Authors:  J SCHNEEWEISS; G W POOLE
Journal:  Br Med J       Date:  1960-09-17

Review 2.  Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

Authors:  Pooja Gopal; Gerhard Grüber; Véronique Dartois; Thomas Dick
Journal:  Trends Pharmacol Sci       Date:  2019-11-06       Impact factor: 14.819

Review 3.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

4.  Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Authors:  Emily R Driver; Gavin J Ryan; Donald R Hoff; Scott M Irwin; Randall J Basaraba; Igor Kramnik; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

5.  Mechanisms of Pyrazinamide Action and Resistance.

Authors:  Ying Zhang; Wanliang Shi; Wenhong Zhang; Denis Mitchison
Journal:  Microbiol Spectr       Date:  2013

6.  Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.

Authors:  Halimah Sayahi; Oren Zimhony; William R Jacobs; Alexander Shekhtman; John T Welch
Journal:  Bioorg Med Chem Lett       Date:  2011-06-29       Impact factor: 2.823

7.  Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Authors:  Laura E Via; Rada Savic; Danielle M Weiner; Matthew D Zimmerman; Brendan Prideaux; Scott M Irwin; Eddie Lyon; Paul O'Brien; Pooja Gopal; Seokyong Eum; Myungsun Lee; Jean-Philippe Lanoix; Noton K Dutta; TaeSun Shim; Jeong Su Cho; Wooshik Kim; Petros C Karakousis; Anne Lenaerts; Eric Nuermberger; Clifton E Barry; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2015-05-08       Impact factor: 5.084

Review 8.  The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors.

Authors:  Kyle H Rohde; Leonardo Sorci
Journal:  Front Microbiol       Date:  2021-01-26       Impact factor: 5.640

Review 9.  Impact of the host environment on the antitubercular action of pyrazinamide.

Authors:  Elise A Lamont; Anthony D Baughn
Journal:  EBioMedicine       Date:  2019-10-25       Impact factor: 8.143

10.  Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide.

Authors:  Pierre Santucci; Daniel J Greenwood; Antony Fearns; Kai Chen; Haibo Jiang; Maximiliano G Gutierrez
Journal:  Nat Commun       Date:  2021-06-21       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.